{"id":95469,"date":"2025-12-03T10:32:23","date_gmt":"2025-12-03T08:32:23","guid":{"rendered":"https:\/\/www.ipsen.com\/?p=95469"},"modified":"2025-12-03T10:35:03","modified_gmt":"2025-12-03T08:35:03","slug":"pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie","status":"publish","type":"post","link":"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/","title":{"rendered":"Pourquoi l\u2019avenir de la biopharma appartient aux innovateurs agiles, et non aux g\u00e9ants de l\u2019industrie"},"content":{"rendered":"\n<p><em><strong>Christelle Huguet, Vice-Pr\u00e9sidente Ex\u00e9cutive, Responsable de la R&amp;D chez Ipsen<\/strong>, remet en question l\u2019id\u00e9e d\u00e9pass\u00e9e selon laquelle \u00ab plus grand \u00bb signifie \u00ab meilleur \u00bb dans le secteur biopharmaceutique. Elle affirme que c\u2019est l\u2019agilit\u00e9 \u2013 et non la taille \u2013 qui stimule l\u2019innovation de rupture. Gr\u00e2ce \u00e0 la pr\u00e9cision, \u00e0 une prise de d\u00e9cision rapide et \u00e0 une attention constante port\u00e9e aux besoins des patients, des innovateurs agiles comme Ipsen sont pr\u00eats \u00e0 g\u00e9n\u00e9rer un impact concret.<\/em><\/p>\n\n\n\n<p>L\u2019avenir de la biopharma sera fa\u00e7onn\u00e9 non pas par les plus grands acteurs, mais par les plus agiles. C\u2019est pourquoi je crois que notre mod\u00e8le op\u00e9rationnel chez Ipsen nous conf\u00e8re un v\u00e9ritable avantage dans un environnement en constante \u00e9volution.<\/p>\n\n\n\n<p>Nous sommes une entreprise biopharmaceutique mondiale avec un \u00e9tat d\u2019esprit de biotech. Cette position unique nous permet de combiner l\u2019envergure et la port\u00e9e d\u2019une grande organisation avec la concentration et la flexibilit\u00e9 d\u2019une biotech. Cela signifie des d\u00e9cisions plus rapides, une expertise sp\u00e9cialis\u00e9e tout au long du parcours et l\u2019agilit\u00e9 n\u00e9cessaire pour s\u2019adapter \u00e0 l\u2019\u00e9mergence de nouvelles donn\u00e9es et informations \u2013 autant d\u2019\u00e9l\u00e9ments qui nous aident \u00e0 faire progresser rapidement les m\u00e9dicaments prometteurs dans leur d\u00e9veloppement.<\/p>\n\n\n\n<p>Au c\u0153ur de notre approche se trouve un mod\u00e8le de R&amp;D ax\u00e9 sur la science, centr\u00e9 sur ce qui compte le plus : les patients. Nous suivons une strat\u00e9gie claire pour construire un portefeuille l\u00e0 o\u00f9 les options sont limit\u00e9es et les besoins des patients \u00e9lev\u00e9s. Ce sont des domaines qui restent difficiles d\u2019acc\u00e8s ou o\u00f9 peu d\u2019acteurs s\u2019aventurent, mais o\u00f9 nous mettons en \u0153uvre une science convaincante pour lever les obstacles \u00e0 de nouveaux traitements et explorer de nouvelles aires th\u00e9rapeutiques. Ce qui reste essentiel dans cette approche, c\u2019est la flexibilit\u00e9 : travailler ensemble en \u00e9quipe et nous r\u00e9orienter lorsque les donn\u00e9es nous y invitent. Bien que nous commencions avec une feuille de route claire, l\u2019apparition de nouvelles preuves, en particulier en recherche pr\u00e9coce, peut r\u00e9v\u00e9ler des possibilit\u00e9s accrues pour les patients. C\u2019est un exemple concret de ce que signifie \u00ab suivre la science \u00bb en pratique et de la mani\u00e8re dont cette approche nous aide \u00e0 lib\u00e9rer tout le potentiel de nos m\u00e9dicaments pour les patients.<\/p>\n\n\n\n<p>Notre approche transversale se traduit \u00e9galement par une prise de d\u00e9cision plus rapide. Cela implique d\u2019int\u00e9grer nos \u00e9quipes m\u00e9dicales et r\u00e9glementaires d\u00e8s le d\u00e9but du d\u00e9veloppement. Ce faisant, nous am\u00e9liorons l\u2019efficacit\u00e9, exploitons une expertise de bout en bout et nous assurons de prendre les bonnes d\u00e9cisions.<\/p>\n\n\n\n<p>Par-dessus tout, cela montre que l\u2019agilit\u00e9 est essentielle \u2013 pour suivre la science, prendre des d\u00e9cisions pertinentes et, en fin de compte, r\u00e9pondre aux besoins des patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Christelle Huguet, Vice-Pr\u00e9sidente Ex\u00e9cutive, Responsable de la R&amp;D chez Ipsen, remet en question l\u2019id\u00e9e d\u00e9pass\u00e9e selon laquelle \u00ab plus grand<\/p>\n","protected":false},"author":97,"featured_media":95466,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[81827],"tags":[],"class_list":["post-95469","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science-2","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pourquoi l\u2019avenir de la biopharma appartient aux innovateurs agiles, et non aux g\u00e9ants de l\u2019industrie - Global<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pourquoi l\u2019avenir de la biopharma appartient aux innovateurs agiles, et non aux g\u00e9ants de l\u2019industrie - Global\" \/>\n<meta property=\"og:description\" content=\"Christelle Huguet, Vice-Pr\u00e9sidente Ex\u00e9cutive, Responsable de la R&amp;D chez Ipsen, remet en question l\u2019id\u00e9e d\u00e9pass\u00e9e selon laquelle \u00ab plus grand\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-03T08:32:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-03T08:35:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/12\/Rectangle-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1090\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"emie\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"emie\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/\"},\"author\":{\"name\":\"emie\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/a0f231a95044132e1295dd6b00f339b4\"},\"headline\":\"Pourquoi l\u2019avenir de la biopharma appartient aux innovateurs agiles, et non aux g\u00e9ants de l\u2019industrie\",\"datePublished\":\"2025-12-03T08:32:23+00:00\",\"dateModified\":\"2025-12-03T08:35:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/\"},\"wordCount\":511,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/12\/Rectangle-1.png\",\"articleSection\":[\"Science\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/\",\"name\":\"Pourquoi l\u2019avenir de la biopharma appartient aux innovateurs agiles, et non aux g\u00e9ants de l\u2019industrie - Global\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/12\/Rectangle-1.png\",\"datePublished\":\"2025-12-03T08:32:23+00:00\",\"dateModified\":\"2025-12-03T08:35:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/12\/Rectangle-1.png\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/12\/Rectangle-1.png\",\"width\":1090,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pourquoi l\u2019avenir de la biopharma appartient aux innovateurs agiles, et non aux g\u00e9ants de l\u2019industrie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/a0f231a95044132e1295dd6b00f339b4\",\"name\":\"emie\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e3bc24640199849cf7c9cfaa79cb49dc93e3d4e03a9e50a0dc791bd1a408a70f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e3bc24640199849cf7c9cfaa79cb49dc93e3d4e03a9e50a0dc791bd1a408a70f?s=96&d=mm&r=g\",\"caption\":\"emie\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pourquoi l\u2019avenir de la biopharma appartient aux innovateurs agiles, et non aux g\u00e9ants de l\u2019industrie - Global","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/","og_locale":"fr_FR","og_type":"article","og_title":"Pourquoi l\u2019avenir de la biopharma appartient aux innovateurs agiles, et non aux g\u00e9ants de l\u2019industrie - Global","og_description":"Christelle Huguet, Vice-Pr\u00e9sidente Ex\u00e9cutive, Responsable de la R&amp;D chez Ipsen, remet en question l\u2019id\u00e9e d\u00e9pass\u00e9e selon laquelle \u00ab plus grand","og_url":"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/","og_site_name":"Global","article_published_time":"2025-12-03T08:32:23+00:00","article_modified_time":"2025-12-03T08:35:03+00:00","og_image":[{"width":1090,"height":628,"url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/12\/Rectangle-1.png","type":"image\/png"}],"author":"emie","twitter_card":"summary_large_image","twitter_creator":"@ipsengroup","twitter_site":"@ipsengroup","twitter_misc":{"Written by":"emie","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/"},"author":{"name":"emie","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/a0f231a95044132e1295dd6b00f339b4"},"headline":"Pourquoi l\u2019avenir de la biopharma appartient aux innovateurs agiles, et non aux g\u00e9ants de l\u2019industrie","datePublished":"2025-12-03T08:32:23+00:00","dateModified":"2025-12-03T08:35:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/"},"wordCount":511,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/12\/Rectangle-1.png","articleSection":["Science"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/","url":"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/","name":"Pourquoi l\u2019avenir de la biopharma appartient aux innovateurs agiles, et non aux g\u00e9ants de l\u2019industrie - Global","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/12\/Rectangle-1.png","datePublished":"2025-12-03T08:32:23+00:00","dateModified":"2025-12-03T08:35:03+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/#primaryimage","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/12\/Rectangle-1.png","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/12\/Rectangle-1.png","width":1090,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/science-2\/pourquoi-lavenir-de-la-biopharma-appartient-aux-innovateurs-agiles-et-non-aux-geants-de-lindustrie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Pourquoi l\u2019avenir de la biopharma appartient aux innovateurs agiles, et non aux g\u00e9ants de l\u2019industrie"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/a0f231a95044132e1295dd6b00f339b4","name":"emie","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e3bc24640199849cf7c9cfaa79cb49dc93e3d4e03a9e50a0dc791bd1a408a70f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e3bc24640199849cf7c9cfaa79cb49dc93e3d4e03a9e50a0dc791bd1a408a70f?s=96&d=mm&r=g","caption":"emie"}}]}},"jetpack_featured_media_url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/12\/Rectangle-1.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts\/95469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/97"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/comments?post=95469"}],"version-history":[{"count":3,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts\/95469\/revisions"}],"predecessor-version":[{"id":95474,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts\/95469\/revisions\/95474"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media\/95466"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=95469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=95469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=95469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}